Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Stock Information for Oragenics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oragenics Inc.

Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K
Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment
Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health
Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.